A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
28 01 2021
Historique:
received: 24 02 2020
accepted: 05 08 2020
pubmed: 2 9 2020
medline: 26 5 2021
entrez: 2 9 2020
Statut: ppublish

Résumé

A multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has recently been developed to improve outcome predictions and tailor therapeutic decisions, including hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML). We assessed the performance of the KB in guiding HSCT decisions in first complete remission (CR1) in 656 AML patients younger than 60 years from the ALFA-0702 trial (NCT00932412). KB predictions of overall survival (OS) were superior to those of European LeukemiaNet (ELN) 2017 risk stratification (C-index, 68.9 vs 63.0). Among patients reaching CR1, HSCT in CR1, as a time-dependent covariate, was detrimental in those with favorable ELN 2017 risk and those with negative NPM1 minimal residual disease (MRD; interaction tests, P = .01 and P = .02, respectively). Using KB simulations of survival at 5 years in a scenario without HSCT in CR1 (KB score), we identified, in a similar time-dependent analysis, a significant interaction between KB score and HSCT, with HSCT in CR1 being detrimental only in patients with a good prognosis based on KB simulations (KB score ≥40; interaction test, P = .01). We could finally integrate ELN 2017, NPM1 MRD, and KB scores to sort 545 CR1 patients into 278 (51.0%) HSCT candidates and 267 (49.0%) chemotherapy-only candidates. In both time-dependent and 6-month landmark analyses, HSCT significantly improved OS in HSCT candidates, whereas it significantly shortened OS in chemotherapy-only candidates. Integrating KB predictions with ELN 2017 and MRD may thus represent a promising approach to optimize HSCT timing in younger AML patients.

Identifiants

pubmed: 32871585
pii: S0006-4971(21)00151-8
doi: 10.1182/blood.2020005524
doi:

Substances chimiques

NPM1 protein, human 0
Nuclear Proteins 0
Nucleophosmin 117896-08-9

Banques de données

ClinicalTrials.gov
['NCT00932412']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

524-532

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 by The American Society of Hematology.

Auteurs

Laurène Fenwarth (L)

Unité Mixte de Recherche (UMR) 9020-UMR1277, Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre Hospitalo-Universitaire (CHU) Lille, Institut de Recherche sur le Cancer de Lille (IRCL), Lille, France.

Xavier Thomas (X)

Service d'Hématologie Clinique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.

Stéphane de Botton (S)

Département d'Hématologie, Institut Gustave Roussy, Villejuif, France.

Nicolas Duployez (N)

Unité Mixte de Recherche (UMR) 9020-UMR1277, Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre Hospitalo-Universitaire (CHU) Lille, Institut de Recherche sur le Cancer de Lille (IRCL), Lille, France.

Jean-Henri Bourhis (JH)

Département d'Hématologie, Institut Gustave Roussy, Villejuif, France.

Auriane Lesieur (A)

Unité Mixte de Recherche (UMR) 9020-UMR1277, Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre Hospitalo-Universitaire (CHU) Lille, Institut de Recherche sur le Cancer de Lille (IRCL), Lille, France.

Gael Fortin (G)

Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.

Paul-Arthur Meslin (PA)

Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.

Ibrahim Yakoub-Agha (I)

CHU de Lille, University of Lille, INSERM U1286, Infinite, Lille, France.

Pierre Sujobert (P)

Service d'Hématologie Biologique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.

Pierre-Yves Dumas (PY)

Service d'Hématologie et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.

Christian Récher (C)

Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.

Delphine Lebon (D)

Service d'Hématologie Clinique, CHU Amiens, Amiens, France.

Céline Berthon (C)

Unité Mixte de Recherche (UMR) 9020-UMR1277, Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre Hospitalo-Universitaire (CHU) Lille, Institut de Recherche sur le Cancer de Lille (IRCL), Lille, France.
Service d'Hématologie, CHU Lille, Lille, France.

Mauricette Michallet (M)

Service d'Hématologie Clinique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.

Arnaud Pigneux (A)

Service d'Hématologie et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.

Stéphanie Nguyen (S)

Service d'Hématologie Clinique, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Sylvain Chantepie (S)

Service d'Hématologie Clinique, CHU Caen, Caen, France.

Norbert Vey (N)

Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France.

Emmanuel Raffoux (E)

Service Hématologie Adultes, Hôpital Saint-Louis, AP-HP, Paris, France.

Karine Celli-Lebras (K)

Acute Leukemia French Association Coordination Office, Institut de Recherche Saint-Louis (IRSL), Hôpital Saint-Louis, Paris, France.

Claude Gardin (C)

Service d'Hématologie Clinique, Hôpital Avicenne, AP-HP, Bobigny, France.

Juliette Lambert (J)

Département d'Hématologie Clinique, Hôpital André Mignot, Centre Hospitalier de Versailles, Le Chesnay, France.

Jean-Valère Malfuson (JV)

Service d'Hématologie Clinique, Hôpital d'Instruction des Armées Percy, Clamart, France.

Denis Caillot (D)

Service d'Hématologie Clinique, CHU Dijon, Dijon, France.

Sébastien Maury (S)

Service d'Hématologie Clinique, Hôpital Henri Mondor, AP-HP, Créteil, France.

Benoît Ducourneau (B)

Unité Mixte de Recherche (UMR) 9020-UMR1277, Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre Hospitalo-Universitaire (CHU) Lille, Institut de Recherche sur le Cancer de Lille (IRCL), Lille, France.
Laboratoire d'Hématologie, CH Valenciennes, Valenciennes, France.

Pascal Turlure (P)

Service d'Hématologie Clinique, CHU Limoges, Limoges, France.

Emilie Lemasle (E)

Service d'Hématologie, Centre Henri Becquerel, Rouen, France.

Cécile Pautas (C)

Service d'Hématologie Clinique, Hôpital Henri Mondor, AP-HP, Créteil, France.

Sylvie Chevret (S)

Service de Biostatistiques et Informatique Médicale, Hôpital Saint-Louis, AP-HP, Paris, France.

Christine Terré (C)

Laboratoire d'Hématologie, CH Versailles, Le Chesnay, France; and.

Nicolas Boissel (N)

Service Hématologie Adolescents Jeunes Adultes and.

Gérard Socié (G)

Service Hématologie Greffe, Hôpital Saint-Louis, AP-HP, Paris, France.

Hervé Dombret (H)

Service Hématologie Adultes, Hôpital Saint-Louis, AP-HP, Paris, France.

Claude Preudhomme (C)

Unité Mixte de Recherche (UMR) 9020-UMR1277, Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, Centre National de la Recherche Scientifique (CNRS), INSERM, Centre Hospitalo-Universitaire (CHU) Lille, Institut de Recherche sur le Cancer de Lille (IRCL), Lille, France.

Raphael Itzykson (R)

Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, Paris, France.
Service Hématologie Adultes, Hôpital Saint-Louis, AP-HP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH